USP9X can stabilize MCL-1 to promote tumor cell survival through removing the Lys 48-linked polyubiquitin chains that normally mark MCL-1 for proteasomal degradation, which serves as a prognostic and therapeutic target of human malignancies [49]. This evidence concerns the gene MCL1 and neoplasm.